A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 Compared to Humalog in Children, Adolescents, and Adults with Type 1 Diabetes Mellitus

Eli Lilly and Company0 个研究点目标入组 45 人开始时间: 2017年10月26日最近更新: 2019年12月16日

适应症

试验速览

暂无简介。

•Male or female participants aged 6-64 with Type 1 Diabetes Mellitus (T1DM) for at least 1 year
•Glycated hemoglobin (HbA1c) less than (<)10.0 percent (%)
•Have had no episodes of severe hypoglycaemia in the last 6 months
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 30
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 15
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Receiving any oral or injectable medication intended for the treatment of diabetes mellitus other than insulins in the 12 months prior to screening
•Presence of clinically significant hematologic, oncologic, renal, cardiac, hepatic, or gastrointestinal disease, proliferative retinopathy, uncontrolled celiac disease, uncontrolled hyperthyroidism or hypothyroidism, or adrenal insufficiency
•Have obvious clinical signs or symptoms of liver disease
•Have a history of renal impairment

发起方